Literature DB >> 19666155

First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.

V Bouchez1, D Brun, T Cantinelli, G Dore, E Njamkepo, N Guiso.   

Abstract

Bordetella pertussis isolates not expressing Pertussis Toxin (PT) or Pertactin (PRN) have been collected, for the first time in 2007, in France, a highly vaccinated country with acellular vaccines. Non-expression was due to deletion of the entire ptx locus, to IS481 insertion in the prn gene or deletion of a part of this gene. Genome sequencing does not indicate any regions of differences when compared to other circulating isolates. It nevertheless shows some sequence differences and an increased number of repeated sequences. The infant infected by the isolate not expressing pertussis toxin, did not present hyperlymphocytosis. All isolates were found less pathogen in animal or cellular models; their circulation raises the problem of clinical and biological diagnoses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666155     DOI: 10.1016/j.vaccine.2009.07.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  59 in total

1.  Significant finding of Bordetella holmesii DNA in nasopharyngeal samples from French patients with suspected pertussis.

Authors:  Elisabeth Njamkepo; Stéphane Bonacorsi; Monique Debruyne; Sophie Anne Gibaud; Sophie Guillot; Nicole Guiso
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

Review 2.  The Bordetella pertussis model of exquisite gene control by the global transcription factor BvgA.

Authors:  Kimberly B Decker; Tamara D James; Scott Stibitz; Deborah M Hinton
Journal:  Microbiology       Date:  2012-05-24       Impact factor: 2.777

3.  Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.

Authors:  Neelima Sukumar; Gina Parise Sloan; Matt S Conover; Cheraton F Love; Seema Mattoo; Nancy D Kock; Rajendar Deora
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

Review 4.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

Review 5.  Bordetella pertussis: new concepts in pathogenesis and treatment.

Authors:  Nicholas H Carbonetti
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

6.  Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality.

Authors:  M E Gaillard; D Bottero; C E Castuma; L A Basile; D Hozbor
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

7.  Bordetella pertussis naturally occurring isolates with altered lipooligosaccharide structure fail to fully mature human dendritic cells.

Authors:  Jolanda Brummelman; Rosanne E Veerman; Hendrik Jan Hamstra; Anna J M Deuss; Tim J Schuijt; Arjen Sloots; Betsy Kuipers; Cécile A C M van Els; Peter van der Ley; Frits R Mooi; Wanda G H Han; Elena Pinelli
Journal:  Infect Immun       Date:  2014-10-27       Impact factor: 3.441

8.  Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.

Authors:  Abdolreza Advani; Hans O Hallander; Tine Dalby; Karen Angeliki Krogfelt; Nicole Guiso; Elisabeth Njamkepo; Carl Heinz Wirsing von Könnig; Marion Riffelmann; Frits R Mooi; Per Sandven; Anna Lutynska; Norman K Fry; Jussi Mertsola; Qiushui He
Journal:  J Clin Microbiol       Date:  2012-11-21       Impact factor: 5.948

9.  Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland.

Authors:  Alex-Mikael Barkoff; Jussi Mertsola; Sophie Guillot; Nicole Guiso; Guy Berbers; Qiushui He
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

10.  Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.